Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a new 52-week high on Thursday . The stock traded as high as $4.66 and last traded at $4.56, with a volume of 1654 shares. The stock had previously closed at $4.39.
The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 3.66.
In related news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $3.00, for a total transaction of $30,000.00. Following the sale, the director now directly owns 919,827 shares of the company’s stock, valued at approximately $2,759,481. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 30,000 shares of company stock worth $102,100. 13.78% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.66” was posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/2018/11/10/imprimis-pharmaceuticals-immy-hits-new-52-week-high-at-4-66/2972540.html.
Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
See Also: Outstanding Shares
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.